Tuesday, October 20, 2026||
MultiKhabarMultiKhabar
Home/finance/Guggenheim raises Rapport Therapeutics price target to $70 on trial data

Guggenheim raises Rapport Therapeutics price target to $70 on trial data

In
Investing.comBy Investing.com
10/20/2026, 6:46:51 PM
Share:WhatsAppFacebookX (Twitter)Telegram
Guggenheim raises Rapport Therapeutics price target to $70 on trial data
EXECUTIVE SUMMARY

Guggenheim raises Rapport Therapeutics price target to $70 on trial data....

Key Takeaways

  • Guggenheim raises Rapport Therapeutics price target to $70 on trial data.

Share:WhatsAppFacebookX (Twitter)Telegram

Read Complete Original Article

Published originally on Investing.com

Visit Publisher Site →
OTHER MEDIA SOURCES COVERING THIS STORY
2 Publishers Reporting
Investing.com
Raymond James raises Rapport Therapeutics price target on bipolar data

Related News

Multikhabar App

All Information In One Place

Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!

Get it on Google Play